Modulation of Plasminogen Activator Inhibitor 1 by Triton X-100 – Identification of Two Consecutive Conformational Transitions^[*]

Summary

Plasminogen activator inhibitor-1 (PAI-1) is a unique member of the serpin superfamily because of its conformational and functional flexibility. In the present study, we have evaluated the influence of the nonionic detergent Triton X-100 (TX-100) on the functional stability and conformational transitions of PAI-1.

At 37° C, TX-100 induced a concentration-dependent decrease of the functional half-life of PAI-1 resulting in half-lives of 177 ± 54 min (mean ± SD, n = 3), 19 ± 2 min, 1.7 ± 0.3 min and 0.53 ± 0.03 min in the presence of 0.005, 0.010, 0.020 and 0.2% TX-100, respectively, compared to a half-life of 270 ± 146 min in the absence of TX-100. Conformational analysis at various time points and at different temperatures (0° C, 25° C, 37° C) revealed that this inactivation proceeds through the formation of a substrate-like intermediate followed by the formation of the latent form. Kinetic evaluation demonstrated that this conversion fits to two consecutive first-order transitions, i.e. active substrate latent. The k₁ value was strongly dependent on the concentration of TX-100 (e.g. 0.002 ± 0.0006 s ^-1 and 0.029 ± 0.003 s ^-1 for 0.01% and 0.2% TX-100 at 37° C) whereas the conversion of substrate to latent (k₂) was virtually independent of the TX-100 concentration (i.e. 0.012 ± 0.002 s ^-1 and 0.011 ± 0.001 s ^-1 for 0.01 and 0.2% TX-100 at 37° C).

Experiments with a variety of other non-ionic amphiphilic compounds revealed that the amphiphilic character of the compound is, at least in part, responsible for the observed effects and strongly indicate that the currently reported mechanism of inactivation is of general importance for the conformational transitions in PAI-1.

In conclusion, TX-100 changes the initial conformation of PAI-1 resulting in altered functional properties. This observation allows us to develop a new model for the mechanism involved in the conformational flexibility of PAI-1 and may provide new insights for the development of strategies for interference with PAI-1 activity.

^* This work was supported in part by a grant from the Research Fund K.U. Leuven (OT/94/27) and by a grant from the Fund for Scientific Research (F.W.O.-Vlaanderen, G.0266.97).

• References

• 1 Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem 1988; 175: 531-40.
• 2 Lawrence DA, Strandberg L, Grundstrom T, Ny T. Purification of active human plasminogen activator inhibitor-1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186: 523-33.
• 3 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 4 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Hemost Thromb 1989; 9: 87-115.
• 5 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
• 6 Declerck PJ, De Mol M, Alessi MC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-61.
• 7 Wiman B, Almquist A, Sirgurdardottir O, Lindahl T. Plasminogen activator inhibitor-1 is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-8.
• 8 Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellullar matrix. Evidence that the protein is vitronectin. J Biol Chem 1989; 264: 5058-63.
• 9 Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-6.
• 10 Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
• 11 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
• 12 Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. Febs Lett 1986; 209: 213-8.
• 13 Ginsburg D, Zeheb R, Young AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
• 14 Ny T, Sawdey M, Lawrence D, Milan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
• 15 Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, Van Zonneveld AJ, Van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 1986; 5: 2539-44.
• 16 Sprang SR. The latent tendencies of PAI-1. Trends Biochem Sci 1992; 17: 49-50.
• 17 Laskowski M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626.
• 18 Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen activator inhibitor-1 and tissue plasminogen activator. Biochem J 1990; 265: 109-13.
• 19 Wei A, Rubin H, Cooperman BS, Christianson DW. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct Biol 1994; 1: 251-8.
• 20 Song HK, Lee KN, Kwon KS, Yu MH, Suh SW. Crystal structure of an un-cleaved α₁-antitrypsin reveals the conformation of its inhibitory reactive site loop. FEBS Lett 1995; 337: 150-4.
• 21 Elliott PR, Lomas DA, Carrell RW, Abrahams JP. Inhibitory conformation of the reactive loop of α₁-antitrypsin. Nature Struct Biol 1996; 3: 676-81.
• 22 Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 1994; 2: 257-70.
• 23 Schreuder HA, deBoer B, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hol WGJ. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1994; 1: 48-54.
• 24 Wright HT, Qian HX, Huber R. Crystal structure of plakalbumin, a proteolytically nicked form of albumin. Its relationship to the structure of cleaved α₁-proteinase inhibitor. J Mol Biol 1990; 213: 513-28.
• 25 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
• 26 Seetharam R, Dwivedi AM, Duke JL, Hayman AC, Walton HL, Huckins NR, Kamerkar SM, Corman JI, Woodeshick RW, Wilk RR, Reilly TM. Purification and Characterization of Active and Latent Forms of Recombinant Plasminogen Activator Inhibitor 1 Produced in Escherichia coli. Biochemistry 1992; 31: 9877-82.
• 27 Vaughan DE, Declerck PJ, Reilly TM, Park K, Collen D, Fasman GD. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). Biochim et Biophys Acta 1993; 1202: 221-9.
• 28 Sancho E, Declerck PJ, Price NC, Kelly SM, Booth NA. Conformational studies on plasminogen activator inhibitor-1 (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 1995; 34: 1064-9.
• 29 Schulze AJ, Quarzago D, Andreasen PA. A spectroscopic study of the structures of latent, active and reactive-center-cleaved type-1 plasminogen-activator inhibitor. Eur J Biochem 1996; 240: 550-5.
• 30 Sancho E, Tonge DW, Hockney RC, Booth N. Purification and characterization of active and stable recombinant plasminogen activator inhibitor (PAI-1) accumulated at high level in Escherichia coli . Eur J Biochem 1994; 224: 125-34.
• 31 Olson S. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. J Biol Chem 1985; 260: 10153-60.
• 32 Patston PA, Gettins P, Beechem J, Shapira M. Mechanism of serpin action: evidence that C1-inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876-82.
• 33 Cooperman BS, Stavridi E, Nickbarg E, Rescoria E, Schechter NM, Rubin H. Antichymotrypsin interaction with chymotrypsin. Partitioning of the complex. J Biol Chem 1993; 268: 23616-25.
• 34 Schechter NM, Jordan LM, James AM, Cooperman BS, Wang ZM, Rubin H. Reaction of human chymase with reactive site variants of alpha 1-anti-chymotrypsin. Modulation of inhibitor versus substrate properties. J Biol Chem 1993; 268: 23626-33.
• 35 Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Eur J Biochem 1996; 241: 38-46.
• 36 Gils A, Declerck PJ. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. J Biol Chem 1997; 272: 12662-6.
• 37 Nielsen LS, Andreasen PA, Grondahl-Hansen J, Skriver L, Dano K. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. (1986) Febs Lett 1986; 196: 269-73.
• 38 Fay WP, Owen WG. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated proteine C. Biochemistry 1989; 28: 5773-8.
• 39 Gils A, Knockaert I, Declerck PJ. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-81.
• 40 Declerck PJ, Collen D. Measurements of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res 1990; Supp X 3-9.
• 41 Strandberg L, Lawrence DA, Johanssson LBA, Ny T. The oxidative inactivation of plasminogen activator inhibitor 1 results from a conformational change in the molecule and does not require the involvement of the P1’ methionine. J Biol Chem 1991; 266: 13852-8.
• 42 Ehnebom J, Björquist P, Andersson JO, Johansson T, Deinum J. Detergent Tween 80 modifies the specific activity of PAI-1. Fibrinolysis & Proteolysis 1997; 11: 165-70.
• 43 Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996; 75: 808-15.